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INTRODUCTION
Since the ﬁrst successful transplantation using umbilical
cord blood (CB) to treat a patient with Fanconi’s anemia in
1988 [1], CB transplantation has generated strong interest
as an alternative to bone marrow transplantation (BMT) to
treat a variety of diseases. Basic research has shown the valu-
able properties of CB that make it not only a viable alterna-
tive but a preferred one for many patients. Clinical studies
support this research through trials that show both the efﬁ-
cacy and accessibility of CB for clinical use [2-6].
As interest in and clinical use of CB increases, several
important issues have moved to the forefront. Among these
are questions about the biological and immunological prop-
erties of CB, practical ways to harvest and store CB in banks,
administrative questions on how to create and introduce
standards into CB banking, and ethical concerns. (These
questions and issues were discussed at a symposium held in
San Francisco on December 1, 2000, at which international
experts presented the most current information on CB bank-
ing and transplantation. The symposium was chaired by
Jeffrey McCullough, MD, University of Minnesota Medical
School. Presenters included Karen Ballen, MD [American
Red Cross], Hal E. Broxmeyer, PhD [Indiana University
School of Medicine], Wanda Piacibello, MD [University of
Torino Medical School], Paolo Rebulla [Milano Cord Blood
Bank], Catherine M. Verfaillie, MD [University of Min-
nesota Medical School], and John E. Wagner, MD [Univer-
sity of Minnesota Medical School].)
CLINICAL STATUS OF CB TRANSPLANTATION
CB transplantation offers the potential to increase the
availability of blood to treat a variety of diseases and has
shown several advantages over allogeneic BMT: (1) immediate
availability, (2) less HLA restriction for donors, (3) lower risk
of viral contamination of the graft, and (4) potentially reduced
risk of graft-versus-host disease (GVHD) [7]. Currently, there
have been more than 1000 CB transplantations performed
worldwide from related and unrelated donors to treat patients
with malignant and nonmalignant diseases [7,8] (Table 1).
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ABSTRACT
Cord blood (CB) transplantation has expanded the ability of the transplantation community to meet the growing
needs of their patients. Clinical data over the last decade show promising results in CB transplantation using blood
from related as well as unrelated donors. Basic science continues to look for ways to expand the quality and quantity
of CB. CB banks are now established around the world, with major efforts to standardize banking to facilitate regu-
lation, collection, processing, and distribution as a way of providing the highest-quality CB for patient use. This
review article discusses the current status of CB transplantation and banking in the United States and Europe.
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Clinical results of related and unrelated donor CB trans-
plantation are now available from many institutions world-
wide. These studies have examined the effect of patient
characteristics (eg, age, weight, disease) and donor blood
characteristics (eg, HLA match, number of nucleated cells
transplanted) on survival, disease-free survival, and engraft-
ment (neutrophil and platelet). Important sources of these
clinical outcomes come from CB registries that contain data
on combined results from many institutions. For related
donor CB transplantations, data from the International Cord
Blood Transplant Registry and the Eurocord Registry pro-
vide combined results on clinical outcomes. For unrelated
donor CB transplantations, two primary registries include
the New York Blood Bank and the Eurocord Registry.
CB Transplantation From a Related (Sibling) Donor
The ﬁrst successful transplantation of CB from a related
donor was performed in 1988 to treat a patient with Fan-
coni’s anemia [1]. A more recent case in 2001 of a successful
CB transplantation in a 6-year-old girl with Fanconi’s ane-
mia treated at the University of Minnesota with CB that was
a selected product of in vitro fertilization and preimplanta-
tion genetic diagnosis exempliﬁes the future promise of CB
transplantation [9]. Several studies over the past decade have
examined the use of CB from a related donor for transplan-
tation. Summary analyses of these individual studies have
been done by the International Cord Blood Transplant Reg-
istry [7,10] and the Eurocord Registry [5,11] (Table 2).
CB Transplantation From an Unrelated Donor
The use of CB from an unrelated donor is thought to
have several advantages: (1) it is more accessible than mar-
row because of reduced HLA restriction; (2) a shorter
interval is required between the search for a donor and
acquiring CB; (3) it poses no risk to the donor; and (4) it
may involve a lower risk of acute GVHD [3-5,12-14]. Clin-
ical studies on CB from unrelated donors suggest that these
advantages are real.
Placental Blood Program at the New York Blood Center.
This study, composed of 98 transplantation centers world-
wide, provides the largest dataset of CB transplantation from
unrelated donors (Table 3). As of 1998, cumulative rates of
engraftment based on actuarial analysis for 562 patients were
81% for neutrophil recovery (median of 28 days) and 85%
for platelet engraftment (median of 90 days). Several factors
were associated with events related to the transplantation,
including degree of HLA disparity, underlying disease,
patient age, number of leukocytes in the graft, and the trans-
plantation center. Leukocytic content of the graft was associ-
ated with the length of time to engraftment, but it was not
signiﬁcantly related to event-free survival after engraftment
(unlike age, which was signiﬁcantly associated with event-free
survival). This suggests that larger doses of leukocytes may
speed up engraftment but may not improve event-free sur-
vival, particularly for older patients [6].
Eurocord Registry. As of April 1998, 158 children and
adults had received CB from unrelated donors through the
Eurocord Registry (composed of 39 transplantation centers
from 15 countries) (Table 3) [5,15,16]. Separate overall
analyses were done for 102 children and 44 adults, as well as
a subset analysis of 42 adults with malignant disease.
Children. The report of 102 children who received
unrelated CB showed an overall 1-year survival rate of
37%; neutrophil engraftment in 74% of patients; incidence
of acute GVHD ≥II in 38% of patients; and overall survival
rates of 35% in patients with malignancies, 10% in patients
with bone marrow failure syndromes, and 70% in patients
with inborn errors. Factors favorably associated with sur-
vival were ABO match (P = .01) and cytomegalovirus
(CMV)-negative status before CB transplantation (P = .02).
No significance was found between survival and weight,
age, number of nucleated cells infused, sex, or HLA dispar-
ity. No association was found between GVHD and the
number of HLA mismatches. (For the 44 adults listed in
this registry during the same time period, the overall sur-
vival rate was 16%.)
Adults With Malignancies. When only the 42 adults with
malignancies were analyzed, overall survival rate at 1 year
was 17%. Factors favorably associated with survival were
cell dose (≥1 × 107/kg) (P = .0001) and having a good risk
status at the time of transplantation (P = .02). The number
of infused nucleated cells ranged from 0.2 to 6 × 107/kg
(median, 1.7 × 107/kg). The 6 patients who received <1 ×
107/kg died. The 1-year survival rate of poor-risk patients
versus good-risk patients was 7% versus 36%. Median time
to neutrophil recovery (≥500/mm3) was 35 days; median
time to platelet engraftment (≥20,000/mm3) was 176 days.
Acute GVHD (>grade II), observed in 18 patients, was not
associated with HLA disparities (P = .58) [15].
These studies indicate that CB transplantation beneﬁts
children with malignant disease, deﬁcient immune systems,
or inborn errors, whereas it may be less beneﬁcial in adults
and in patients with bone marrow failure syndromes, espe-
cially poor-risk adults (Table 3).
Table 1. Diseases Treated by Cord Blood Transplantation*
Malignant diseases
Acute lymphocytic leukemia
Acute myelocytic leukemia
Chronic myelogeneous leukemia
Juvenile chronic myelogeneous leukemia
Myelodysplastic syndrome
Neuroblastoma
Nonmalignant Diseases
Adrenoleukodystrophy
Amegakaryocytic thrombocytopenia
Blackfan-Diamond syndrome
Dyskeratosis congenita
Fanconi’s anemia
Globoid cell leukodystrophy
Gunther disease
Hunter syndrome
Hurler syndrome
Idiopathic aplastic anemia
Kostman syndrome
Lesch-Nyhan syndrome
Osteopetrosis
Severe combined immune deficiency
Thalassemia
X-linked lymphoproliferative syndrome
*Adapted from Fasouliotis and Schenker [8].
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Duke University and University of Minnesota Study
The University of Minnesota and Duke University have
collaborated on the study of unrelated donor CB transplanta-
tion for 7 years. A subset of 257 patients was selected for
analysis based on the following criteria: (1) patients had to
have received a transplantation at least 100 days prior to
analysis; (2) patients had to have received cytoreductive ther-
apy prior to CB transfusion; and (3) donor and recipient pairs
had to have HLA disparity of 0 to 3 antigens. Of these
patients, 164 (64%) had malignant diseases (most with acute
leukemia) and 93 (36%) had nonmalignant diseases. Most
patients received a 2-mm HLA mismatch (48%). All patients
received prophylactic treatment for GVHD, with the major-
ity receiving cyclosporin A plus low-dose methylprednisolone
(72%). Prophylactic granulocyte colony–stimulating factor
(G-CSF) was given to 153 patients, either 5 µg/kg (17%) or
10 µg/kg (74%) (Wagner, presentation at CME symposium,
San Francisco, California, December 1, 2000).
Results from this subset study show the following:
• Survival. The overall survival rate was 50% at 1 year
and 41% at 3 years. Analysis by risk factors showed a
better survival for (1) younger patients (similar to
BMT), (2) patients treated with more than 1.5 ×
107/kg cell dose, (3) patients who received CD34+ cell
dose of more than 1.5 × 105/kg, and (4) patients who
were Caucasian (similar to BMT).
• Engraftment. Neutrophil engraftment was achieved in
87% of patients at a median of 25 days. Platelet recov-
ery was achieved in 51% of patients at a median of
6 months. Of all the demographic, graft, and treat-
ment risk factors analyzed, nucleated cell dose (× 107)
had the most effect on engraftment. Cell doses lower
than 1.5 × 107 show a delay in recovery and an inferior
engraftment. These data suggest that 1.5 × 107 should
be the lowest acceptable graft dose.
• GVHD. Only 12% of patients experienced acute
GVHD (grades III-IV), a rate that is about half of
what was expected even in a pediatric population
receiving transplants of bone marrow. Analysis by
risk factors did not show any association between
acute GVHD and HLA match or age. The most
dramatic difference with CB was found for chronic
GVHD, which occurred in only 7% of patients with
no difference between adult and pediatric popula-
tions. Analysis by risk factors showed a trend toward
higher incidence of GVHD in patients treated with
melphalan.
Overall, this study showed that CB transplantation from
an unrelated donor was associated with (1) a high rate of
engraftment in recipients of ≥1.5 × 105 CD43+ cells/kg
recipient weight, (2) a delay in platelet engraftment of
6 months (median) that was dependent on cell dose, (3) a
delayed neutrophil recovery of 25 days (median) that was
dependent on cell dose, (4) a low rate of acute and chronic
GVHD even with a high degree of HLA disparity, and (5)
high risk of regimen-related mortality in recipients of low
cell doses. Based on the clinical experience at Duke Univer-
sity and University of Minnesota, the cell dose of 1.5 × 107
Table 2. Studies of Cord Blood Transplantation From Related (Sibling) Donors
International Cord Blood
Transplantation Registry [10] Eurocord Registry [5,11]
Number of patients 62 102
Median age, y (range) (0.5-16) 5 (0.2-20)
Median body weight, kg (range) — 19 (5-50) 
Diseases, n — Malignancies (61)
— Nonmalignancies (41)
Number of HLA mismatches, n 0 (51) 0 (80)
1-3 (11) 1 (5)
2 (6)
3 (10)
4 (10)
Overall survival at 1 year — 64%
Survival by HLA status 61% at 2 y (0-1 HLA disparity) 73% at 1 y (0 HLA disparity)
50% at 1 y (1-4 HLA disparity)
(P = .006)
Survival at 1 year by disease — 55% (malignancies)
67% (bone marrow
failure syndrome)
100% (hemoglobinopathies)
71% at 1 y (inborn errors) 
Incidence of GVHD 6/62 (grades 0-1) 24% (grade >II)
3/62 (grades II-IV) 7% (grades II-IV)
3/62 (chronic) 3 of 43 patients at risk (chronic)
Neutrophil engraftment, d (median)* 9-46 (22) 8-49 (28)
Platelet engraftment, d (median)† 15-117 (51) 4-180 (48)
*Neutrophil recovery deﬁned as time to achieve an absolute neutrophil count >5 × 108/L.
†Platelet count >5 × 1010/L untransfused for 7 days.
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nucleated cells per kilogram patient weight would appear to
be the threshold dose for safety of CB transplantations.
National Heart, Lung, and Blood Institute Study
A prospective safety and efficacy study of unrelated
donors for CB transplantation initiated in 1998 by the
National Heart, Lung, and Blood Institute is designed to fur-
ther test whether CB provides an adequate source of hemato-
poietic progenitor cells for all or only a subgroup of patients.
The primary end point is 180-day survival, with everyday end
points of disease-free survival, engraftment, incidence and
severity of GVHD, relapse, infection, and immune reconsti-
tution. Patients will be stratiﬁed on the basis of HLA dispar-
ity: 6/6 and 5/6 versus 4/6 versus 3/6 and <3/6 [17]. This
study is presently underway and no results are yet available.
General Conclusions From Studies: Places for
Further Research
The results of these studies point to several areas in
need of further research.
Nucleated Cell Dose. The threshold dose of nucleated
cells that is adequate for successful engraftment for adults
and children must be established. Most data show a signiﬁ-
cant decrease in survival in adult patients infused with
≤1.5 × 107/kg nucleated cells. The New York Blood Bank,
Eurocord, and the combined University of Minnesota and
Duke University studies all indicate a strong dose relation-
ship between nucleated cell dose and engraftment.
Disease Stage and Engraftment. The inﬂuence of dis-
ease state on delayed or successful engraftment in patients
with speciﬁc diseases should be determined. The New York
Table 3. Studies of Cord Blood Transplantation From Unrelated Donors
University
New York Eurocord Registry Eurocord Registry of Minnesota/
Blood Center [6] [5,15,16] [5,15,16] Duke University* 
Number of patients 562 158† 42‡ 257
Age, y (n) <2 (114) Children: 0.2-14 (102) 15-50 (median, 26) 0.2-58 (median, 8.1)
2-5 (127) Adults: (44)
6-11 (137)
12-17 (82)
≥18 (102)
Body weight, kg (n) <10 (77) 5-46 (102) 35-90 (median, 56) 3.9-102.8 (median, 24.5)
10-19 (148)
20-39 (152)
40-59 (91)
≥60 (94)
Diseases (n) Leukemia or lymphoma Leukemia or lymphoma Acute leukemia (16) Malignancies (164) 
(378) (72 children) Chronic myeloid leukemia (21) Nonmalignancies (93)
Genetic disease (137) Bone marrow failure Non-Hodgkin’s lymphoma (2)
Acquired disease (47) syndrome (12 children) Myelodysplastic syndromes (3)
Inborn errors (18 children)
Malignancies (42 adults)
Number of HLA 0 (40) Children: 0 (14) 0 (2) 0 (18)
mismatches (n) 1 (218) 1 (64) 1 (8) 1 (91)
2 (261) 2 (23) 2 (21) 2 (124)
3 (37) 3 (1) 3 (10) 3 (15)
4 (3) Adults: 0 (6) 4 (1) Unresolved (9)
1 (17)
2 (14)
3 (5)
Platelets engraftment 85% at 180 d (90 d) — — 51% (6 mo)
(median time)
Neutrophil engraftment 81% at 42 d (28 d) 74% for children 76 ± 12 at 60 d 87% (25 d) 
(median time)
Incidence of GVHD (grade) 23% acute (III-IV) 38% acute (≥II) 18 acute (≥II) 30% acute (≥II)
25% chronic 3 chronic 12% acute (III-IV)
7% chronic
Survival rate (disease) Children: 37% (overall) 17% ± 6% (overall) 41% at 3 years
35% (malignancies)
10% (bone marrow 
failure syndrome)
70% (inborn errors)
Adults: 16% (overall)
*Data presented at CME symposium.
†Patients analyzed were divided into 2 groups: children (n = 102) and adults (n = 44).
‡Separate analysis of 42 adult patients with malignancies.
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Blood Center found that certain diseases, such as chronic
myelogenous leukemia and aplastic anemia, were more likely
to have graft failure. In contrast, the combined study from
the University of Minnesota and Duke University found only
a relationship between aplastic anemia and Fanconi’s anemia
and graft failure. However, these latter diseases are also asso-
ciated with graft failure after unrelated donor BMT.
HLA Status and GVHD. The inﬂuence of HLA status
on the incidence of GVHD must be established. This state-
ment is supported by a recent study of HLA-identical sib-
lings that found a lower incidence of acute and chronic
GVHD in CB recipients compared with bone marrow
recipients from HLA-identical siblings [7]. The studies
summarized here do not show a relationship between HLA
disparity and GVHD, and the rates of GVHD seem lower
than expected from historical experience.
This encouraging clinical experience increases the
importance of basic research into the biological and
immunological properties of CB to improve the effective-
ness of CB transplantation [10,12].
BIOLOGICAL RESEARCH: EXPANSION AND
TRANSDUCTION OF CB CELLS
Because successful engraftment depends on an adequate
dose of hematopoietic stem cells (HSCs), CB is currently
limited as a graft for adult transplant recipients. In addition,
increasing cell dose may shorten the time to engraftment
and thus improve the success of the therapy. Finding ways to
expand the dose of HSCs in CB is therefore one of the pri-
mary goals in current CB transplantation research. Expan-
sion of these cells is based on the theory that the unique
properties of HSCs, which include the capacity of long-term
marrow reconstitution and the ability to generate large
numbers of committed progenitors with progressively
restricted differentiation potential, should be retained after
these cells are transplanted in the clinical setting. A number
of protocols have been designed for the ex vivo expansion of
CB HSCs, a sampling of which are discussed below. These
studies also examine whether cultures that support CB HSC
expansion allow retroviral transduction and whether
engrafted cells in culture possess self-renewal activity.
CB Expansion Studies
Adult marrow contains a greater number of CD34+ cells
than does CB (ie, frequencies of CD34+ cells are about .01%
to 1.0% nucleated cells in CB and about 1% to 3% nucle-
ated cells in adult bone marrow).
However, CB has a higher in vitro proliferation or expan-
sion potential than does adult bone marrow, as illustrated by
in vivo studies of NOD/SCID mice [18]. Because of the
capacity of CB HSC to expand, several investigators are
attempting to expand these cells ex vivo with the hope of
eventually making these cells available for clinical use in the
transplantation setting [19,20]. Studies in laboratory mice
show that early and late engraftments in mice depend on stem
cell dose, and mice that received transplants of only commit-
ted progenitors had graft failure. In humans, supplementation
of committed progenitors results in earlier engraftment.
Therefore, early and long-term engraftments require both
expansion of committed progenitors and stem cells.
Most studies on CB expansion, until recently, have used
the antigen CD34+ and its subsets to detect the presence of
HSCs in vitro. The immunophenotype CD34+CD38– is
thought to deﬁne a subgroup of primitive progenitor cells
that have a higher cloning efficiency in CB than in adult
bone marrow. Cells with this immunophenotype in CB also
expand more rapidly when stimulated by cytokines inter-
leukin (IL)-3, IL-6, and stem cell factor (SCF). [8]. More
recent evidence suggests that there are some HSCs that do
not express CD34 antigens [21-23], and therefore investiga-
tors are using a variety of culture conditions and assays to
expand the HSCs in CB.
University of Minnesota Experience
Culture Conditions for CB Expansion. The AFT04 cul-
ture system, in which immortalized myoﬁbroblasts (MSCs)
derived from mouse fetal liver are used to support MSC, has
been shown to (1) support repopulating murine stem cells for
more than 6 weeks in vitro [24] and (2) support human CB,
bone marrow, peripheral blood long-term culture initiating
cell (LTC-IC), and extended LTC-IC in both “contact” and
“noncontact” cultures. This culture system (transwells above
the AFT024 feeder) was used in a number of experiments to
evaluate expansion and transduction of CB HSCs. The in
vivo assays of SCID repopulation were used to measure CB
HSC in CB cells that were transplanted in NOD-SCID mice
[25] and preimmune fetal sheep [26]. The in vitro assay used
to measure primitive progenitors that could undergo self-
renewal and differentiation to lymphoid and myeloid lineages
was the myeloid-lymphoid initiating cell (ML-IC) assay [27].
Verfaillie and colleagues showed that AFT024 noncon-
tact cultures of CD34+ CD38–Lin– cells using different com-
binations of cytokines (FS7 = F1t3-L, SCF, IL7; FS7T =
F1t3-L, SCF, IL7, thrombopoietin [Tpo]; FT = Flt3-L,
Tpo) were able to induce expansion of committed and prim-
itive progenitor cells. At 5 weeks, there was a 15-fold expan-
sion of CD34+Lin– CB colony-forming cells (CFC), a 5-fold
expansion of LTC-ICs, and a 10-fold expansion of natural
killer-initiating cells (NK-ICs) [27]. In addition, they
showed that the AFT024 noncontact culture supports main-
tenance of ML-IC. These studies show that very primitive
progenitor cells are maintained in the culture system and
suggest that stem cells may also be preserved in these cul-
tures even though they have not yet been able to be
expanded. Using this same noncontact culture showed that
CB ML-ICs were able to undergo self-renewing cell divi-
sions in vitro [27].
Cells capable of engrafting NOD-SCID mice are main-
tained as demonstrated in the limiting dilution assay
showing that the number of SCID repopulating cells
(SRCs) that engraft in primary and secondary animals is
similar in unmanipulated cells and cultured cells at 7 days or
14 days. No engraftment has been seen in tertiary animals
with unmanipulated or manipulated cells. When trans-
planted in fetal sheep, no difference in engraftment was
found between unmanipulated cells and cultured cells at 7
days. These experiments show that self-renewing cells and
committed progenitor cells can be maintained ex vivo. This
culture system also supports the transduction of 50% to
80% CB LTC-IC, ML-IC, and SRCs with an GALV-
pseudotyped eGFP retrovirus.
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Because of growing evidence that the CD34 antigen is
not present on all HSCs [21-23], Verfaillie and colleagues
tested whether the AFT024 feeder culture system would
support ML-IC in CB CD34–Lin–CD38– cells. They found
that cultures with FT (Flt3-L and Tpo) generate CD34+Lin–
cells with ML-IC ability. This finding shows that the
AFT024 feeder culture system supports both CD34+ and
CD34– CB HSCs.
To test for a more clinically suitable culture system
(because noncontact cultures cannot be used in the clinic),
Verfaillie and colleagues used cultures with media condi-
tioned by the AFT024 feeder or with “artiﬁcial conditioned
medium” with cytokines and extracellular matrix compo-
nents secreted by the AFT024 feeder to test whether similar
results could be obtained. They found that in “artiﬁcial con-
ditioned medium” cultures, cells capable of repopulating
NOD-SCID mice can be maintained to the same extent and
that these cultures can support expansion of more commit-
ted CFC and LTC-IC that is equal to or greater than expan-
sion in AFT024 noncontact cultures [28,29].
Retroviral Transduction of Expanded Progenitors.
Because similar expansion of progenitors and similar
preservation of SRCs were found in stroma-free systems
compared to AFT024 noncontact systems, it is also important
to determine whether similar transduction can be obtained
in these culture systems. In AFT024 noncontact culture sys-
tems, 60% to 80% (mean, 74%) of CB CD34+Lin– ML-ICs
are transduced and >80% of CB CD34+Lin– SRCs are trans-
duced. However, despite expansion of CB CFC, CB LTC-IC,
and CB NK-IC in a stroma-free system, there is poor trans-
duction of these progenitor cells. They found that the dose of
GAGs used in these cultures is an important determinant for
successful transduction. High doses of 10 µg/mL prevented
transduction of progenitors, whereas lower doses of 5 µg/mL
allowed for transduction. Other studies have shown successful
engraftment of NOD-SCID mice with retrovirally trans-
duced CB [30-35].
Summary. As a result of this work, culture methods are
available that allow both progenitor expansion and transduc-
tion and that are suitable for the clinical setting. In the labo-
ratory setting, AFT024 noncontact culture supplemented
with FT (Flt3-L, Tpo) supports the following:
• expansion of committed CB CD34+ progenitors and
maintenance (and possibly expansion) of primitive CB
CD34+ ML-IC and SRC;
• transduction of CB CD34+ committed and primitive
progenitors with murine retrovirus based vectors; and
• generation of CD34+ ML-IC from the quiescent
CD34+ stem cell pool.
Stroma-free cultures, based on factors present in
AFT024 conditioned medium, (1) support expansion of
committed CB CD34+ progenitors and maintenance (with
the possibility of expansion) of primitive CB CD34+ ML-IC
and SRC; and (2) can prevent transduction of progenitors if
the dose of GAGs added to the artificially conditioned
medium is too high.
Two clinical trials now underway are testing the time to
and durability of engraftment and the contribution of
expanded graft to early and late engraftment by either
restriction fragment length polymorphism (RFLP) or retro-
viral marking.
University of Torino Experience
Culture Conditions for CB expansion. A miniwell
expansion system using stroma-free cultures of CD34+ cells
was used to expand HSC in the laboratory setting. This lab-
oratory system showed that a degree of stem cell self-
renewal could be triggered under certain culture conditions.
This system used a number of assays for in vitro detection of
committed progenitors (semisolid cultures, colony-forming
units–granulocyte/macrophage [CFU-GM], burst-forming
unit-erythroid [BFU-E], CFU-megakaryocyte); more primitive
progenitors (multipotent colony-forming units [CFU-
GEMM], CFU-B1, high proliferative potential [HPP]-
CFC, PRE-CFC); and surrogate in vitro assays for “putative
stem cells” (long-term cultures: LTC-IC, at 5, 8, and
12 weeks). CB CD34+ cells can be maintained in culture for
more than 7 months in a stroma-free, serum-containing
system in the presence of the cytokines Flk2/Flt3 ligand
(FL) and Tpo, with or without c-kit ligand (or SCF). In
these cultures, CB CD34+ can undergo massive expansion:
20-million-fold for progenitors and 270,000-fold for more
primitive LTC-ICs [18,36].
Engraftment Capacity in NOD/SCID. Using an in vivo
transplantation model in irradiated SCID and NOD/SCID
mice, CB NOD/SCID long-term in vivo repopulating
CD34+ cells could be expanded 70-fold after 9 to 10 weeks
in cultures that included FL, TPO, and SCF with or with-
out IL-6 [37]. Fetal calf serum can be replaced by human
serum without impairing the ability of the expanded cells to
engraft to the sublethally irradiated recipients [37].
There is a low level of engraftment in mice receiving
transplants of low amounts of puriﬁed CD34+ CB cells (2 ×
104), but increasing levels of engraftment with increased
amounts of CD34+ cells and in the manipulated (expanded)
cells. This indicates that inoculation with accessory CD34–
cells and with CD34+++ cells has no effect on the degree of
engraftment, and therefore accessory cells do not play a role in
the increased ability of expanded CD34+++ cells to repopulate.
Self-Renewal Ability of Engrafted Cells. Human CB
CD34+ cells expanded for 4 or 6 weeks were able to com-
pletely and durably repopulate the bone marrow of a mye-
loablated NOD/SCID mouse, and human CD34+ cells
retrieved from the engrafted bone marrow could repopulate
the marrow of a secondary irradiated recipient.
Summary. These studies have shown the following:
• Accessory cells do not affect the increased ability of
expanded CD34+++ cells to repopulate.
• Engrafted human cells retain their self-renewal capacity.
• Characterization of culture conditions that allow
human hematopoietic stem cell expansion is an
important requirement for the successful implemen-
tation of many clinical transplantation and gene ther-
apy protocols.
• These studies represent a signiﬁcant step toward the
practical realization of such approaches. 
IMMUNOLOGICAL RESEARCH: PROPERTIES OF CB
The recent publication of a large study [7] that conﬁrms
earlier preclinical and clinical studies that suggested a lower
incidence of GVHD in CB stem and progenitor cell trans-
plantation [38-40] raises several issues about the immuno-
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logic properties of CB. This section summarizes recent
studies that show differences between CB immune cells and
immune recovery after CB transplantation.
Differences in Immune Cells Between CB and Adult
Blood/Bone Marrow
There have been a number of reports in which a compar-
ison between immune cell types and function of CB cells with
adult blood or bone marrow cells have suggested that CB
immune cells may be more immature and less functionally
active than their adult counterparts [40-43]. For example, CB
T cells manifest less cytotoxic activity than adult T cells after
primary, secondary, and tertiary allogeneic cell stimulation
[44,45]. Moreover, whereas CB T cells respond as well as
adult T cells to the proliferation-inducing activity of a pri-
mary allogeneic stimulation, CB T cells, in contrast to adult
T cells, become unresponsive to secondary allogeneic stimu-
lation. Adult T cells proliferate to an even a greater extent
after secondary compared to primary allogeneic stimulation
[46]. The mechanisms of this tolerance of CB T cells to sec-
ondary allogeneic cell stimulation reﬂect the intracellular sta-
tus of the CB T cells in that the inactive guanosine diphos-
phate (GDP)-bound form of Ras is not activated to the active
guanosine triphosphate (GTP) form [47]. More recent studies
note that human CB has few or no cells with a CD8+ natural
killer (NK) T-cell phenotype. However, IL-12 and IL-15
were found crucial to induction of CD8+ NKT cell develop-
ment [48]. This development was associated with expression
of the co-stimulating receptor 41BB. Because NKT cells are
potent cytotoxic cells, it is possible that lack of these cells in
CB may account, in at least part, for the previously noted low
allogeneic cytotoxicity by CB T cells.
Recovery of Immune System After CB
Transplantation
The relative immaturity of some immune cells in CB
presents a potential problem for recovery of immune cells
after CB transplantation. A study from Indiana School of
Medicine was conducted in part to evaluate immune recovery
in patients receiving CB from an unrelated donor [49].
Twenty-seven patients (14 male and 13 female), with a
median age of 4.85 years (range, 0.4-17.1 years) and a median
weight of 18.4 kg (range, 5.65-71.4 kg), received a total of
30 transplants between November 1994 and February 1999.
For immune parameters, T-cell recovery was 9 to 12 months,
B-cell recovery was 6 months, and NK-cell recovery was
2 months. For cell function recovery, T-cell recovery was 6 to
9 months, B-cell recovery (immunoglobins) remained in the
normal range with nadirs between 1 and 3 months, and NK-
cell recovery was 1 month in all children.
Immune Recovery and Cell Dose. The study by Thom-
son and colleagues [49] found (1) no relationship between
the rate of T-, B-, and NK-cell numerical recovery com-
pared to nucleated cells/kg infused and CD34 cells/kg
infused, (2) only a weak association between phytohemag-
glutinin (PHA) recovery and nucleated cells/kg infused, (3)
no relationship between the rate of T-, B-, and NK-cell
numerical recovery and degree of HLA mismatch, (4) only a
weak relationship between CD8 cell recovery and grade ≥II
GVHD, (5) a total of 13 grade II and 3 grade IV infections
in the ﬁrst 100 days after transplantation, and (6) no correla-
tion between grade of infection and time to immune recov-
ery in this series (which at 27 is small).
Summary. These studies summarize some knowledge
on the immunological properties of CB and areas that need
further research:
• Lower numbers of CD8+ NKT cells in CB compared
to adult peripheral blood may account for the weak
cytotoxicity of T cells in CB.
• Low or absent CD8+ NKT cells in CB may be
involved in the lowered GVHD noted after CB trans-
plantation.
• Studies are needed to test CD8+ NKT cells after CB
transplantation, considering that induction of CB
CD8+ NKT cells may be associated with antitumor
activity.
CB BANKING
With the increased recognition that CB is a viable
source of hematopoietic cells for transplantation, the need
for making available large numbers of high-quality CB units
has led to the creation of CB banks worldwide. CB banking
has several potential beneﬁts: (1) rapid availability of CB, (2)
no donor risk or attrition, (3) low risk of transmitting infec-
tious diseases, (4) potentially reduced risk of acute GVHD,
and (5) possible increased ability to expand the pool of
donors to include ethnic and racial minorities [10].
The ﬁrst operational CB banks were established in 1993
in New York, Milan, and Düsseldorf. Other CB banks have
since followed worldwide. Although as of November 2000,
Bone Marrow Donors Worldwide (BMDW) estimated the
current worldwide inventory of CB as 54,157 units, it is esti-
mated that this number probably exceeds 70,000 units. This
number is the sum of the 54,157 units listed by BMDW; the
14,000 units stored in 20 banks located in Japan [9], China
[6], Korea [3], Thailand [1], and Singapore [1] (T. Taka-
hashi, written communication); and the approximately 3,000
units present in some banking programs not yet listed by the
BMDW. The establishment of these banks, and the subse-
quent development of coalitions of CB banks and organiza-
tions devoted to establishing quality, require addressing sev-
eral issues, some of which have been successfully addressed
and others that remain debated.
Table 4. Considerations in Establishing a Cord Blood Bank
Specific Issues Unresolved Issues
Donor Recruitment Adequate cell dose
Consent Speed of engraftment
Donor Suitability Histocompatibility requirement
Collection Expansion potential
Stem cell selection or red Optimum processing procedures
cell depletion Duration of storage
Preservation Autologous use potential
Histocompatibility testing Role of maternal cells in CB
Genetic diseases testing Role of genetic testing for disease
Transplant specimens Approaches for testing opportunistic 
Transportation diseases
Thawing and transfusion
Confidentiality
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Major Issues of CB Banking
Many of the major issues involved with the establish-
ment of a CB bank are similar to the issues involved with
the establishment of traditional blood banks. Techniques
to efﬁciently and safely select donors and to collect, store,
process, and distribute CB units to areas of need through-
out the world have been developed, with ongoing assess-
ment of ways to improve these techniques [50-52]. Other
issues remain unresolved, with studies underway to
address them (Table 4). Among these issues are the biologi-
cal and immunological unknowns of CB that basic science
researchers are studying, such as adequate cell dose, speed of
engraftment, and expansion potential. Other areas involve
the unknowns of long-term storage. A recent examination of
defrosted CB samples that were processed, stored, and
frozen for up to 15 years at Indiana University School of
Medicine suggests that long-term durability of cryopre-
served CB cells is viable given the high, efﬁcient recovery
these stem and progenitor cells maintained, along with
extensive capacity for proliferation and differentiation
(Broxmeyer, presentation at the CME symposium).
All of these issues are vitally important to the establish-
ment of high-quality CB banks. Quality of CB banking
refers to both the quality of the product (CB) and the qual-
ity of the systems used to make CB available. In recognition
that development of CB banks depends on establishing
product standards and quality systems, several organizations
have been formed to ensure the highest standard of CB col-
lection, exchange, and transportation nationally and interna-
tionally (Table 5).
CB Banking: American Red Cross
As of November 2000, 38% (19,948 CB units) of the
BMDW ﬁle was contributed by 6 banking programs in the
United States, one of which is the American Red Cross. The
American Red Cross Cord Blood Program was established
in 1998 and has focused on the following goals.
Creating Multiple Sites. Four regional sites have been
created to collect and process CB nationwide. Currently, a
total of 2000 HLA units have been collected and processed at
the 4 sites. All of these CB units are from allogenic donors.
Each site, representing a different national geographical and
ethnic community, is pursuing speciﬁc research goals:
1. The Columbus Program (Ross Cord Blood Program)
was the ﬁrst program developed by the American Red
Cross. CB is collected by trained staff of the American
Red Cross. The program’s primary interest is in ex
vivo expansion and improved processing methods.
2. The Western Area Program includes collection and
processing sites in San Diego, California, and Port-
land, Oregon, and is the fastest-growing program.
The goal of this program is to collect 30,000 blood
cord units from ethnically diverse populations over
the next 5 years. Current blood collection shows that
57% of the donors are white, 25% Hispanic (making
this site the largest collection of CB from Hispanic
donors), and 18% are from other ethnic groups. Sim-
ilar to the Columbus site, CB is collected by Ameri-
can Red Cross trained staff.
3. The North Central Area Program includes collection
and processing sites in Minneapolis and St. Paul, Min-
nesota. This program is speciﬁcally studying the con-
sent process (including paternal consent) and techniques
for the short-term liquid preservation of CB stem cells.
4. The New England Region Program began in 1997 at
the University of Massachusetts and was acquired by
the American Red Cross in 1999. CB is collected by
trained obstetrical staff using the technique of the
placenta in utero. This program is studying donor
characteristics and Phase I clinical trials.
Developing Common Investigational New Drug Appli-
cations and Procedures. A main goal of the American Red
Cross is to establish common procedures and standards.
Central to this goal is the need to address a number of ethi-
cal issues.
Increasing Minority Recruitment. Because the majority
of CB units currently available are disproportionately from
Caucasian donors, there is a strong need to increase donor
participation by other ethnic groups. Along with developing
multiple collection and processing sites nationwide to
include the many diverse ethnic groups in the United States,
the American Red Cross also is involved with studies speciﬁ-
cally targeting minority recruitment.
A multicenter study through the National Marrow
Donor Program and 5 CB Banks (Worchester, New York,
Denver, San Diego, and Gainesville) and the corresponding
bone marrow donors in each geographical location was initi-
ated in 1998 to compare minority recruitment of CB donors
with minority recruitment of bone marrow donors. Two end
points were studied: (1) the race of CB donors compared
with the race of all women who delivered babies at partici-
pating hospitals, and (2) the race of bone marrow donors
compared with race of geographical area based on Census
data. A limitation to the study was the way in which the
racial makeup of the donors was obtained, which was simply
through completing a self-reported questionnaire. The
results of the study showed that (1) the number of recruited
CB units from minority donors was always less than the
number of minority women giving birth; and (2) none of the
CB banks recruits a higher percentage of minorities com-
pared to the baseline delivery population than do the bone
marrow donor centers compared to the baseline Census
Table 5. Selected Organizations That Ensure Quality and Standards in
Cord Blood Banking*
American Association of Blood Banks (AABB)
American Red Cross (ARC)
Bone Marrow Donors World (BMDW)
Cord Blood Transplantation Study (COBLT)
European Blood and Marrow Transplant Group (EBMT)
Eurocord
Foundation for the Accreditation of Hematopoietic Cell Therapy 
(FAHCT)
Group for the Collection and Expansion of Hematopoietic Cells 
(GRACE)
International Society for Hematotherapy and Graft Engineering 
(ISHAGE)
Joint Accreditation Committee of ISHAGE-Europe and EBMT (JACIE)
NETCORD
National Bone Marrow Donor Program (NMDP)
*From Rebulla, presentation at CME symposium.
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population. Overall, the study found no advantage of CB
compared to bone marrow in terms of minority recruitment,
which indicates a need for improved strategies to increase
minority donor participation.
Participating in CB Banking, Research, and Clinical
Investigation. A number of research projects are underway
by the American Red Cross, including studies on cytokine
expansion, engraftment into immunodeficient mice, donor
selection, minority recruitment, consent process, and process
and collection techniques. Three major studies are currently
underway for the year 2001: (1) CB donor evaluation (dis-
cussed below), (2) optimization of HPC recovery from CB
during processing, and (3) expansion of stored CB cells.
The Cord Blood Donor Evaluation study included more
than 1200 donors from the New England Program site and
compared donor (donor age, race, smoking history) and
baby (birth order, weight, and sex) characteristics to labora-
tory parameters of the processed CB units (volume, nucle-
ated cell counts, CD34 counts, and CFU-GM). Results of
the study showed that (1) large volume units correlated with
higher nucleated cell counts, CD34, and CFU-GM; (2) no
effect was found between maternal age or race on any of the
lab parameters; (3) smokers had lower CD34 counts; and (4)
ﬁrst babies, as well as bigger babies, had higher nucleated
cell counts, CD34, and CFU-GM. A multivariate analysis of
the effect of smoking, number of previous births, gestation
duration, and birth weight on total nucleated cell count,
CD34 count, and CFU-GM found that birth weight had the
largest effect on all counts. For every 500-g increase in
weight, there was a corresponding 10% increase in total
nucleated cell count, 28% increase in CD34 count, and 21%
increase in CFU-GM. The results indicate that (1) bigger
babies and ﬁrst babies may be better CB donors, (2) data can
be used to select the best CB donors and to preserve
resources, and (3) banks can expand and provide more avail-
able CB units by optimal use of resources.
CB Banking in Europe
As of November 2000, 54% of the BMDW ﬁle was con-
tributed by European banks (29,152 CB units). Analysis of
the Eurocord database (E. Gluckman and V. Rocha, Paris,
written communication) and of the existing published
reports indicates that about 20% of CB transplantations so
far performed worldwide were provided by European banks
(Table 6). Soon after the establishment of the ﬁrst CB banks
in Europe (Milan CB Bank and the Düsseldorf CB Bank), a
major concern was the importance of helping physicians
select high-quality CB. From this concern evolved the idea
of combining the resources of CB banks to ensure quality.
Group for the Collection and Expansion of Hemato-
poietic Cells. The ﬁrst attempt at combining resources was
initiated by the Milan Cord Blood Bank in 1995. The
Group for the Collection and Expansion of Hematopoietic
Cells, called GRACE, was created to facilitate communica-
tion among clinicians and investigators in Italy [53]. This
national model linked banks to a central hub in Milan.
Seven banks became members of this organization, 5 of
which (Milan, Turin, Florence, Rome, Padua) had Interna-
tional Organization for Standardization (ISO) 9002 status.
ISO 9002 is a model for quality assurance developed in 1987
and updated in 1994; it includes 20 clauses on procedures,
organizational structure, processes, and resources for CB
banking. A bank with a ISO 9002 status is certiﬁed as com-
pliant with the speciﬁc clauses denoting quality in CB bank-
ing [54]. Several protocols were formally approved by
GRACE, including (1) CB collection, characterization, and
cyropreservation; (2) CB unit data transmission; (3) CB unit
extended search, shipment, and patient follow-up; and (4)
clinical protocol for related and unrelated CB transplanta-
tion. The success of this program encouraged the possibility
of exporting it internationally to provide clinicians access to
CB information, to create harmonization among CB banks,
and to ensure quality assurance on a worldwide level.
Netcord. In March 1997, a pilot program called Netcord
was initiated to fulfill this goal. It was a combined effort
between the Milan and Düsseldorf CB banks to share
inventories of CB by using a software program to perform
searches of shared inventory. In 1997-1998, the number of
duplicate searches dropped significantly, only 16% of
2,953 searches. In 1998, CB banks in London and Barcelona
joined the group. From 1998, this group evolved into a con-
solidated international network of banks linked to 2 hubs
(1 in Milan and 1 in Düsseldorf) that could search the whole
inventory. This group operates on standards that were pub-
lished in June 2000 by Netcord and the Foundation for the
Accreditation of Hematopoietic Cell Therapy in a publica-
tion called The International Standards and Inspection
Checklist for Cord Blood Collection, Processing, Testing,
Banking, Selection, and Release (first edition). As of
November 2000, 23,835 units were available and 235 units
transplanted (1995-2000) from the 2 hubs that link a num-
ber of participating CB banks in Düsseldorf, Milan, New
York, Barcelona, Denver, Leiden, London, Paris, St. Louis,
and Tokyo. The program continues to evolve, with many
other countries applying for participation. Several systems
in place help with the movement of information: the Euro-
cord Registry does patient follow-up, and the recent cre-
ation of a virtual ofﬁce now allows searches on the Internet.
CONCLUSION
CB transplantation has expanded the ability of the trans-
plantation community to meet the growing needs of their
patients. Clinical data over the last decade show promising
results in CB transplantation using blood from related as
Table 6. European Cord Blood Banking Programs
Austria
Belgium
Bruxelles (Leuven)
Czekia
Düsseldorf
Finland
France (Paris, Besancon, Bordeaux)
Germany (Ulm)
Italy (GRACE: Florence, Milan, Padua, Rome, Turin)
Netherlands
Spain (Barcelona, Malaga, Galicia, Madrid, Valencia, Canarias)
Switzerland
London
Warsaw
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well as unrelated donors. Basic science continues to look for
ways to expand the quality and quantity of CB. CB banks
are now established around the world, and major efforts are
underway to standardize banking to facilitate regulation,
collection, processing, and distribution as a way of providing
the highest-quality CB for patient use.
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